In the mouse model of PD using 6-hydroxydopamine (6-OHDA) lesions, metformin was found to inhibit the development of dyskinesia and modulate Akt and glycogen synthase kinase 3 (GSK3) signaling, as well as astrocyte activation [249,254]. This evidence concerns the gene AKT1 and Parkinson disease.